Mativ Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Q1 delivered record margin and cash flow since the merger, with adjusted EBITDA up 28% year-over-year. Despite input cost inflation and healthcare demand softness, pricing actions and portfolio strength support a positive outlook for 2026.
-
The meeting covered formal business, including the election of directors, auditor ratification, executive compensation approval, and an amendment to the equity plan. All proposals passed, and no shareholder questions were raised during the session.
Fiscal Year 2025
-
Delivered strong 2025 results with record free cash flow, margin expansion, and debt reduction despite soft demand and macro headwinds. FAM segment led growth, while SAS faced volume challenges but improved margins. 2026 outlook targets further cost savings, disciplined investment, and continued deleveraging.
-
Q3 saw strong year-over-year growth in sales, Adjusted EBITDA, and free cash flow, with both SAS and FAM segments contributing. Strategic initiatives and cost controls are driving margin expansion and deleveraging, despite ongoing macroeconomic and tariff challenges.
-
Q2 2025 delivered strong sequential and year-over-year growth in sales, adjusted EBITDA, and free cash flow, driven by volume gains, cost reductions, and strategic execution. Full-year 2025 cash flow is expected to double 2024, with continued margin and operational improvements anticipated.
-
Q1 results were mixed, with SAS segment growth offset by FAM segment weakness and a $412M goodwill impairment. Leadership is focused on urgent cost reductions, deleveraging, and a strategic portfolio review to restore profitability and reduce leverage.
-
The meeting covered board and executive updates, approved all four proposals including director election, auditor ratification, executive compensation, and an equity plan amendment. No questions were raised by stockholders during the session.
Fiscal Year 2024
-
SaaS segment drove strong growth in Q4 and 2024, while FAM faced challenges from weak industrial demand and prior quality issues. Cost reductions, portfolio optimization, and targeted investments are expected to support profit and margin improvement in 2025.
-
Q3 2024 saw flat sales but a 10% rise in adjusted EBITDA, driven by SAS growth and cost reductions. Films remain challenged by weak end markets and competition, but turnaround efforts and strategic investments are underway. Demand recovery is sluggish, with a cautious outlook for 2025.
-
Q2 2024 saw strong adjusted EBITDA growth, driven by pricing discipline, operational improvements, and volume gains, especially in SAS. Outlook for the rest of 2024 is stable, with continued focus on cost management, growth investments, and debt reduction.